Zhe-yu Y. Hu

No. 283, Tongzipo Road
Changsha, 410013, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Real-world efficacy and prognostic factors of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China.

Real-world efficacy and prognostic factors of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: June 28, 2025

BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study.

BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study.

Journal: Breast (Edinburgh, Scotland)

Published: March 19, 2025

Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study.

Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: a Chinese multicenter real-world study.

Journal: The oncologist

Published: February 22, 2025

Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real-world evidence in metastatic breast cancer.

Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real-world evidence in metastatic breast cancer.

Journal: Cancer innovation

Published: April 11, 2024

Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody.

Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody.

Journal: Breast (Edinburgh, Scotland)

Published: September 21, 2023

The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study.

The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study.

Journal: BMC cancer

Published: September 20, 2023

Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial.

Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial.

Journal: BMC medicine

Published: December 08, 2022

Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.

Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.

Journal: Frontiers in endocrinology

Published: October 21, 2022

Artificial intelligence scale-invariant feature transform algorithm-based system to improve the calculation accuracy of Ki-67 index in invasive breast cancer: a multicenter retrospective study.

Artificial intelligence scale-invariant feature transform algorithm-based system to improve the calculation accuracy of Ki-67 index in invasive breast cancer: a multicenter retrospective study.

Journal: Annals of translational medicine

Published: August 16, 2022

The prognosis and risk factors for capecitabine maintenance treatment in metastatic breast cancer: a retrospective comparative cohort study.

The prognosis and risk factors for capecitabine maintenance treatment in metastatic breast cancer: a retrospective comparative cohort study.

Journal: Annals of translational medicine

Published: March 02, 2022

Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study.

Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study.

Journal: EClinicalMedicine

Published: February 04, 2022

Impact of surgical management of primary tumors in stage IV breast cancer patients: a retrospective observational study based on SEER database.

Impact of surgical management of primary tumors in stage IV breast cancer patients: a retrospective observational study based on SEER database.

Journal: BMJ open

Published: February 02, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026